ID   TLR4_RAT                Reviewed;         835 AA.
AC   Q9QX05;
DT   11-FEB-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   24-JUL-2024, entry version 171.
DE   RecName: Full=Toll-like receptor 4;
DE            Short=Toll4;
DE   AltName: CD_antigen=CD284;
DE   Flags: Precursor;
GN   Name=Tlr4;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Heart;
RX   PubMed=10430608; DOI=10.1172/jci6709;
RA   Frantz S., Kobzik L., Kim Y.-D., Fukazawa R., Medzhitov R., Lee R.T.,
RA   Kelly R.A.;
RT   "Toll4 (TLR4) expression in cardiac myocytes in normal and failing
RT   myocardium.";
RL   J. Clin. Invest. 104:271-280(1999).
RN   [2]
RP   INDUCTION BY LIPOPOLYSACCHARIDES.
RX   PubMed=30980393; DOI=10.1002/jcp.28614;
RA   Chao C.N., Lai C.H., Badrealam K.F., Lo J.F., Shen C.Y., Chen C.H.,
RA   Chen R.J., Viswanadha V.P., Kuo W.W., Huang C.Y.;
RT   "CHIP attenuates lipopolysaccharide-induced cardiac hypertrophy and
RT   apoptosis by promoting NFATc3 proteasomal degradation.";
RL   J. Cell. Physiol. 234:20128-20138(2019).
CC   -!- FUNCTION: Transmembrane receptor that functions as a pattern
CC       recognition receptor recognizing pathogen- and damage-associated
CC       molecular patterns (PAMPs and DAMPs) to induce innate immune responses
CC       via downstream signaling pathways. At the plasma membrane, cooperates
CC       with LY96 to mediate the innate immune response to bacterial
CC       lipopolysaccharide (LPS). Also involved in LPS-independent inflammatory
CC       responses triggered by free fatty acids, such as palmitate, and Ni(2+).
CC       Mechanistically, acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B
CC       activation, cytokine secretion and the inflammatory response.
CC       Alternatively, CD14-mediated TLR4 internalization via endocytosis is
CC       associated with the initiation of a MYD88-independent signaling via the
CC       TICAM1-TBK1-IRF3 axis leading to type I interferon production. In
CC       addition to the secretion of proinflammatory cytokines, initiates the
CC       activation of NLRP3 inflammasome and formation of a positive feedback
CC       loop between autophagy and NF-kappa-B signaling cascade. In complex
CC       with TLR6, promotes inflammation in monocytes/macrophages by
CC       associating with TLR6 and the receptor CD86. Upon ligand binding, such
CC       as oxLDL or amyloid-beta 42, the TLR4:TLR6 complex is internalized and
CC       triggers inflammatory response, leading to NF-kappa-B-dependent
CC       production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling
CC       pathway, and CCL5 cytokine, via TICAM1 signaling pathway. In myeloid
CC       dendritic cells, vesicular stomatitis virus glycoprotein G but not LPS
CC       promotes the activation of IRF7, leading to type I IFN production in a
CC       CD14-dependent manner. {ECO:0000250|UniProtKB:O00206}.
CC   -!- SUBUNIT: Belongs to the lipopolysaccharide (LPS) receptor, a multi-
CC       protein complex containing at least CD14, LY96 and TLR4. Binding to
CC       bacterial LPS leads to homodimerization. Interacts with LY96 via the
CC       extracellular domain. Interacts with MYD88 and TIRAP via their
CC       respective TIR domains. Interacts with TICAM2. Interacts with NOX4.
CC       Interacts with CNPY3 and HSP90B1; this interaction is required for
CC       proper folding in the endoplasmic reticulum. Interacts with MAP3K21;
CC       this interaction leads to negative regulation of TLR4 signaling.
CC       Interacts with CD36, following CD36 stimulation by oxLDL or amyloid-
CC       beta 42, and forms a heterodimer with TLR6. The trimeric complex is
CC       internalized and triggers inflammatory response. LYN kinase activity
CC       facilitates TLR4-TLR6 heterodimerization and signal initiation.
CC       Interacts with TICAM1 in response to LPS in a WDFY1-dependent manner.
CC       Interacts with WDFY1 in response to LPS. Interacts with SMPDL3B.
CC       Interacts with CEACAM1; upon lipopolysaccharide stimulation, forms a
CC       complex including TLR4 and the phosphorylated form of SYK and CEACAM1,
CC       which in turn, recruits PTPN6 that dephosphorylates SYK, reducing the
CC       production of reactive oxygen species (ROS) and lysosome disruption,
CC       which in turn, reduces the activity of the inflammasome. Interacts with
CC       RFTN1; the interaction occurs in response to lipopolysaccharide
CC       stimulation. Interacts with SCIMP; the interaction occurs in response
CC       to lipopolysaccharide stimulation and is enhanced by phosphorylation of
CC       SCIMP by LYN (By similarity). This interaction facilitates the
CC       phosphorylation of TLR4 by LYN which elicits a selective cytokine
CC       response in macrophages (By similarity). Interacts with TRAF3IP3 (By
CC       similarity). Interacts with TREM1; this interaction enhances TLR4-
CC       mediated inflammatory response (By similarity). Interacts with
CC       ZG16B/PAUF (By similarity). Interacts with CD82; this interaction
CC       inhibits TLR4-mediated signaling pathway (By similarity).
CC       {ECO:0000250|UniProtKB:O00206, ECO:0000250|UniProtKB:Q9QUK6}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:O00206};
CC       Single-pass type I membrane protein {ECO:0000250|UniProtKB:O00206}.
CC       Early endosome {ECO:0000250|UniProtKB:O00206}. Cell projection, ruffle
CC       {ECO:0000250|UniProtKB:Q9QUK6}. Note=Upon complex formation with CD36
CC       and TLR6, internalized through dynamin-dependent endocytosis.
CC       Colocalizes with RFTN1 at cell membrane and then together with RFTN1
CC       moves to endosomes, upon lipopolysaccharide stimulation.
CC       {ECO:0000250|UniProtKB:O00206}.
CC   -!- INDUCTION: Induced by lipopolysaccharides.
CC       {ECO:0000269|PubMed:30980393}.
CC   -!- DOMAIN: The TIR domain mediates interaction with NOX4.
CC       {ECO:0000250|UniProtKB:O00206}.
CC   -!- PTM: Phosphorylated on tyrosine residues by LYN after binding
CC       lipopolysaccharide. {ECO:0000250|UniProtKB:Q9QUK6}.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family. {ECO:0000305}.
CC   -!- CAUTION: In some plant proteins and in human SARM1, the TIR domain has
CC       NAD(+) hydrolase (NADase) activity (By similarity). However, despite
CC       the presence of the catalytic Asp residue, the isolated TIR domain of
CC       human TLR4 lacks NADase activity (By similarity). Based on this, it is
CC       unlikely that Toll-like receptors have NADase activity.
CC       {ECO:0000250|UniProtKB:O00206, ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF057025; AAC13313.1; -; mRNA.
DR   RefSeq; NP_062051.1; NM_019178.1.
DR   AlphaFoldDB; Q9QX05; -.
DR   SMR; Q9QX05; -.
DR   BioGRID; 247933; 1.
DR   IntAct; Q9QX05; 1.
DR   MINT; Q9QX05; -.
DR   STRING; 10116.ENSRNOP00000014020; -.
DR   ChEMBL; CHEMBL4523480; -.
DR   GlyCosmos; Q9QX05; 15 sites, No reported glycans.
DR   GlyGen; Q9QX05; 15 sites.
DR   PhosphoSitePlus; Q9QX05; -.
DR   PaxDb; 10116-ENSRNOP00000014020; -.
DR   ABCD; Q9QX05; 2 sequenced antibodies.
DR   GeneID; 29260; -.
DR   KEGG; rno:29260; -.
DR   UCSC; RGD:3870; rat.
DR   AGR; RGD:3870; -.
DR   CTD; 7099; -.
DR   RGD; 3870; Tlr4.
DR   eggNOG; KOG4641; Eukaryota.
DR   InParanoid; Q9QX05; -.
DR   OrthoDB; 1207361at2759; -.
DR   PhylomeDB; Q9QX05; -.
DR   Reactome; R-RNO-140534; Caspase activation via Death Receptors in the presence of ligand.
DR   Reactome; R-RNO-166016; Toll Like Receptor 4 (TLR4) Cascade.
DR   Reactome; R-RNO-166166; MyD88-independent TLR4 cascade.
DR   Reactome; R-RNO-2562578; TRIF-mediated programmed cell death.
DR   Reactome; R-RNO-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-RNO-936964; Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE).
DR   Reactome; R-RNO-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-RNO-937072; TRAF6-mediated induction of TAK1 complex within TLR4 complex.
DR   Reactome; R-RNO-9707616; Heme signaling.
DR   Reactome; R-RNO-975163; IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation.
DR   Reactome; R-RNO-9824878; Regulation of TBK1, IKKEpsilon (IKBKE)-mediated activation of IRF3, IRF7.
DR   PRO; PR:Q9QX05; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0010008; C:endosome membrane; ISO:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:RGD.
DR   GO; GO:0046696; C:lipopolysaccharide receptor complex; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0001891; C:phagocytic cup; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; ISO:RGD.
DR   GO; GO:0001726; C:ruffle; IEA:UniProtKB-SubCell.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0001530; F:lipopolysaccharide binding; IDA:RGD.
DR   GO; GO:0001875; F:lipopolysaccharide immune receptor activity; ISS:UniProtKB.
DR   GO; GO:0061809; F:NAD+ nucleotidase, cyclic ADP-ribose generating; IEA:UniProtKB-EC.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:RGD.
DR   GO; GO:0038023; F:signaling receptor activity; ISO:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:RGD.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:InterPro.
DR   GO; GO:0002218; P:activation of innate immune response; ISO:RGD.
DR   GO; GO:0014002; P:astrocyte development; ISO:RGD.
DR   GO; GO:0042100; P:B cell proliferation; ISO:RGD.
DR   GO; GO:0002322; P:B cell proliferation involved in immune response; ISO:RGD.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; ISO:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; ISO:RGD.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; ISO:RGD.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; ISO:RGD.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEP:RGD.
DR   GO; GO:0071346; P:cellular response to type II interferon; ISO:RGD.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; ISO:RGD.
DR   GO; GO:0032497; P:detection of lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IMP:RGD.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IMP:RGD.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:0010467; P:gene expression; ISO:RGD.
DR   GO; GO:0016064; P:immunoglobulin mediated immune response; IEP:RGD.
DR   GO; GO:0006954; P:inflammatory response; ISO:RGD.
DR   GO; GO:0002758; P:innate immune response-activating signaling pathway; IMP:RGD.
DR   GO; GO:0060729; P:intestinal epithelial structure maintenance; ISO:RGD.
DR   GO; GO:0007254; P:JNK cascade; ISO:RGD.
DR   GO; GO:0006691; P:leukotriene metabolic process; IDA:RGD.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0046651; P:lymphocyte proliferation; ISO:RGD.
DR   GO; GO:0042116; P:macrophage activation; ISO:RGD.
DR   GO; GO:0045342; P:MHC class II biosynthetic process; ISO:RGD.
DR   GO; GO:0014004; P:microglia differentiation; ISO:RGD.
DR   GO; GO:0001774; P:microglial cell activation; IDA:RGD.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; ISO:RGD.
DR   GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; ISO:RGD.
DR   GO; GO:0032707; P:negative regulation of interleukin-23 production; ISO:RGD.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:0032689; P:negative regulation of type II interferon production; ISO:RGD.
DR   GO; GO:0022008; P:neurogenesis; ISO:RGD.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; ISO:RGD.
DR   GO; GO:0002537; P:nitric oxide production involved in inflammatory response; ISO:RGD.
DR   GO; GO:0070427; P:nucleotide-binding oligomerization domain containing 1 signaling pathway; ISO:RGD.
DR   GO; GO:0070431; P:nucleotide-binding oligomerization domain containing 2 signaling pathway; ISO:RGD.
DR   GO; GO:0006909; P:phagocytosis; ISO:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; ISO:RGD.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:1903974; P:positive regulation of cellular response to macrophage colony-stimulating factor stimulus; ISO:RGD.
DR   GO; GO:2000343; P:positive regulation of chemokine (C-X-C motif) ligand 2 production; ISO:RGD.
DR   GO; GO:0032722; P:positive regulation of chemokine production; ISO:RGD.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; ISO:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; ISO:RGD.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; ISO:RGD.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISS:UniProtKB.
DR   GO; GO:0032732; P:positive regulation of interleukin-1 production; ISO:RGD.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; ISO:RGD.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISO:RGD.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; ISO:RGD.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISO:RGD.
DR   GO; GO:0050671; P:positive regulation of lymphocyte proliferation; ISO:RGD.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; ISO:RGD.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; ISO:RGD.
DR   GO; GO:1904466; P:positive regulation of matrix metallopeptidase secretion; ISO:RGD.
DR   GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; ISO:RGD.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; ISO:RGD.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; ISO:RGD.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0070430; P:positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway; ISO:RGD.
DR   GO; GO:0070434; P:positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway; ISO:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:RGD.
DR   GO; GO:0010572; P:positive regulation of platelet activation; ISO:RGD.
DR   GO; GO:1903428; P:positive regulation of reactive oxygen species biosynthetic process; ISO:RGD.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; ISO:RGD.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISO:RGD.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:0032729; P:positive regulation of type II interferon production; ISO:RGD.
DR   GO; GO:0002730; P:regulation of dendritic cell cytokine production; ISO:RGD.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032680; P:regulation of tumor necrosis factor production; IMP:RGD.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0009617; P:response to bacterium; ISO:RGD.
DR   GO; GO:0045471; P:response to ethanol; IMP:RGD.
DR   GO; GO:0070542; P:response to fatty acid; IDA:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:1990268; P:response to gold nanoparticle; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:RGD.
DR   GO; GO:0032570; P:response to progesterone; IEP:RGD.
DR   GO; GO:0032526; P:response to retinoic acid; IEP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; IEP:RGD.
DR   GO; GO:0003009; P:skeletal muscle contraction; IEP:RGD.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; ISO:RGD.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; ISO:RGD.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; IDA:RGD.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; ISO:RGD.
DR   GO; GO:0002246; P:wound healing involved in inflammatory response; ISO:RGD.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1.
DR   Gene3D; 3.40.50.10140; Toll/interleukin-1 receptor homology (TIR) domain; 1.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR017241; Toll-like_receptor.
DR   InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR   PANTHER; PTHR24365; TOLL-LIKE RECEPTOR; 1.
DR   PANTHER; PTHR24365:SF521; TOLL-LIKE RECEPTOR 4; 1.
DR   Pfam; PF13855; LRR_8; 3.
DR   Pfam; PF01582; TIR; 1.
DR   PIRSF; PIRSF037595; Toll-like_receptor; 1.
DR   SMART; SM00369; LRR_TYP; 9.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52058; L domain-like; 3.
DR   SUPFAM; SSF52200; Toll/Interleukin receptor TIR domain; 1.
DR   PROSITE; PS51450; LRR; 13.
DR   PROSITE; PS50104; TIR; 1.
PE   2: Evidence at transcript level;
KW   Cell membrane; Cell projection; Disulfide bond; Endosome; Glycoprotein;
KW   Immunity; Inflammatory response; Innate immunity; Leucine-rich repeat;
KW   Membrane; NAD; Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..835
FT                   /note="Toll-like receptor 4"
FT                   /id="PRO_0000034728"
FT   TOPO_DOM        26..638
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        639..659
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        660..835
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          54..75
FT                   /note="LRR 1"
FT   REPEAT          78..99
FT                   /note="LRR 2"
FT   REPEAT          102..123
FT                   /note="LRR 3"
FT   REPEAT          126..147
FT                   /note="LRR 4"
FT   REPEAT          150..171
FT                   /note="LRR 5"
FT   REPEAT          175..198
FT                   /note="LRR 6"
FT   REPEAT          204..224
FT                   /note="LRR 7"
FT   REPEAT          226..247
FT                   /note="LRR 8"
FT   REPEAT          372..381
FT                   /note="LRR 9"
FT   REPEAT          398..420
FT                   /note="LRR 10"
FT   REPEAT          421..442
FT                   /note="LRR 11"
FT   REPEAT          446..467
FT                   /note="LRR 12"
FT   REPEAT          470..491
FT                   /note="LRR 13"
FT   REPEAT          495..516
FT                   /note="LRR 14"
FT   REPEAT          519..540
FT                   /note="LRR 15"
FT   REPEAT          543..564
FT                   /note="LRR 16"
FT   DOMAIN          576..627
FT                   /note="LRRCT"
FT   DOMAIN          670..813
FT                   /note="TIR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT   CARBOHYD        34
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        43
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        75
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        172
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        204
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        237
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        248
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        281
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        307
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        492
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        495
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        524
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        572
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        575
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        622
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        28..39
FT                   /evidence="ECO:0000250|UniProtKB:O00206"
FT   DISULFID        280..304
FT                   /evidence="ECO:0000250|UniProtKB:O00206"
FT   DISULFID        388..389
FT                   /evidence="ECO:0000250|UniProtKB:O00206"
FT   DISULFID        580..606
FT                   /evidence="ECO:0000250|UniProtKB:O00206"
FT   DISULFID        582..625
FT                   /evidence="ECO:0000250|UniProtKB:O00206"
SQ   SEQUENCE   835 AA;  96072 MW;  DF5E16A30851E3A0 CRC64;
     MMPLLHLAGT LIMALFLSCL RPGSLNPCIE VLPNITYQCM DQNLSKIPHD IPYSTKNLDL
     SFNPLKILRS YSFTNFSQLQ WLDLSRCEIE TIEDKAWHGL NQLSTLVLTG NPIKSFSPGS
     FSGLTNLENL VAVETKMTSL EGFHIGQLIS LKKLNVAHNL IHSFKLPEYF SNLTNLEHVD
     LSYNYIQTIS VKDLQFLREN PQVNLSLDLS LNPIDSIQAQ AFQGIRLHEL TLRSNFNSSN
     VLKMCLQNMT GLHVHRLILG EFKNERNLES FDRSVMEGLC NVSIDEFRLT YINHFSDDIY
     NLNCLANISA MSFTGVHIKH IADVPRHFKW QSLSIIRCHL KPFPKLSLPF LKSWTLTTNR
     EDISFGQLAL PSLRYLDLSR NAMSFRGCCS YSDFGTNNLK YLDLSFNGVI LMSANFMGLE
     ELEYLDFQHS TLKKVTEFSV FLSLEKLLYL DISYTNTKID FDGIFLGLIS LNTLKMAGNS
     FKDNTLSNVF TNTTNLTFLD LSKCQLEQIS RGVFDTLYRL QLLNMSHNNL LFLDPSHYKQ
     LYSLRTLDCS FNRIETSKGI LQHFPKSLAV FNLTNNSVAC ICEYQNFLQW VKDQKMFLVN
     VEQMKCASPI DMKASLVLDF TNSTCYIYKT IISVSVVSVL VVATVAFLIY HFYFHLILIA
     GCKKYSRGES IYDAFVIYSS QNEDWVRNEL VKNLEEGVPR FQLCLHYRDF IPGVAIAANI
     IQEGFHKSRK VIVVVSRHFI QSRWCIFEYE IAQTWQFLSS RSGIIFIVLE KVEKSLLRQQ
     VELYRLLSRN TYLEWEDNAL GRHIFWRRLK KALLDGKALN PDETSEEEQE ATTLT
//
